Although survival analyses for OS in the chemoimmunotherapy cohort and PFS in the chemotherapy-alone cohort did not reach statistical significance, both demonstrated clinically relevant adverse prognostic trends.
← all excerpts
Prognostic impact of baseline blood biomarkers in SCLC first-line treatment.
1
—
—